Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer

被引:5
|
作者
Zhang, Yuxi [1 ]
Xu, Zhipeng [2 ]
Chen, Hui [3 ]
Sun, Xinchen [3 ]
Zhang, Zhaoyue [3 ]
机构
[1] Nanjing Med Univ, Sch Clin Med 1, Nanjing, Peoples R China
[2] Southeast Univ, Affiliated Zhongda Hosp, Dept Urol, Nanjing, Jiangsu, Peoples R China
[3] Jiangsu Prov Hosp, Dept Radiat Oncol, Nanjing, Peoples R China
关键词
INTERNATIONAL EXPERT CONSENSUS; RADIATION-THERAPY; CONSERVING SURGERY; POSTMASTECTOMY RADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY; MOLECULAR SUBTYPES; ENDOCRINE THERAPY; TUMOR; IRRADIATION; TRIAL;
D O I
10.1038/s41598-022-18251-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To compare the survival benefit between preoperative and postoperative radiotherapy for stage I-III non-inflammatory breast cancer patients, we conducted a retrospective cohort study using surveillance, epidemiology and end results databases. Our study recruited patients who had been diagnosed with stage I-III breast cancer and underwent surgery and radiotherapy. The overall survival was calculated by Kaplan-Meier method. Cox risk model was used to determine the impact of radiotherapy according to stage, molecular subtype and other risk factors. Propensity score matching was used to balance measurable confounding factors. Of all the 411,279 enrolled patients varying from 1975 to 2016, 1712 patients received preoperative radiotherapy, and 409,567 patients received postoperative radiotherapy. Compared with the postoperative radiotherapy group, the preoperative radiotherapy group showed significantly higher risks of overall mortality and breast cancer-specific mortality. Survival differences in treatment sequences were correlated with stage, molecular subtypes and other risk factors. According to the results of this study, preoperative radiotherapy did not show a survival advantage, and postoperative radiotherapy is still the primary treatment. However, preoperative radiotherapy also has some theoretical advantages, such as phase reduction and recurrence reduction. Therefore, it is still worthy of further exploration.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Preoperative Radiotherapy versus postoperative Radiotherapy after neoadjuvant Chemotherapy ("NeoRad") in High-risk Breast Cancer: a prospective, randomized, international multicenter Phase III Study
    Matuschek, Christiane
    Jazmati, Danny
    Krug, David
    Corradini, Stefanie
    Fehm, Tanja
    Ruckhaeberle, Eugen
    Kuehn, Thorsten
    Stickeler, Elmar
    Nestle-Kraemling, Carolin
    Holtschmidt, Johannes
    Nekljudova, Valentina
    Loibl, Sibylle
    Budach, Wilfried
    ONKOLOGIE, 2024, 30 (09): : 840 - 844
  • [42] Safety and Efficacy of Pegylated Liposomal Doxorubicin-based Adjuvant Chemotherapy in Patients with Stage I-III Triple-negative Breast Cancer
    Lien, Ming-Yu
    Liu, Liang-Chih
    Wang, Hwei-Chung
    Yeh, Ming-Hsin
    Chen, Chih-Jung
    Yeh, Su-Peng
    Bai, Li-Yuan
    Liao, Yu-Min
    Lin, Chen-Yuan
    Hsieh, Ching-Yun
    Lin, Ching-Chan
    Li, Long-Yuan
    Lin, Po-Han
    Chiu, Chang-Fang
    ANTICANCER RESEARCH, 2014, 34 (12) : 7319 - 7326
  • [43] Nomogram predicts survival benefit from preoperative radiotherapy for non-metastatic breast cancer: A SEER-based study
    Liu, Jianjun
    Su, Mingxue
    Hong, Shikai
    Gao, Hong
    Zheng, Xucai
    Wang, Shengying
    ONCOTARGET, 2017, 8 (30) : 49861 - 49868
  • [44] A comparison study between gross tumor volumes defined by preoperative magnetic resonance imaging, postoperative specimens, and tumor bed for radiotherapy after breast-conserving surgery
    Zhang, Aiping
    Li, Jianbin
    Wang, Wei
    Wang, Yongsheng
    Mu, Dianbin
    Chen, Zhaoqiu
    Shao, Qian
    Li, Fengxiang
    MEDICINE, 2017, 96 (02)
  • [45] Impact of Internal Mammary Lymph Node Drainage Identified by Preoperative Lymphoscintigraphy on Outcomes in Patients With Stage I to III Breast Cancer
    Kong, Amanda L.
    Tereffe, Welela
    Hunt, Kelly K.
    Yi, Min
    Kang, Taewoo
    Weatherspoon, Kimberly
    Mittendorf, Elizabeth A.
    Bedrosian, Isabelle
    Hwang, Rosa F.
    Babiera, Gildy V.
    Buchholz, Thomas A.
    Meric-Bernstam, Funda
    CANCER, 2012, 118 (24) : 6287 - 6296
  • [46] The effect of postoperative radiotherapy on the survival of patients with resectable stage III-N2 non-small-cell lung cancer: a systematic review and meta-analysis
    Zhang, H.
    Zhang, D. X.
    Ju, T.
    Zhou, J.
    NEOPLASMA, 2019, 66 (05) : 717 - 726
  • [47] Comparison of Intraoperative and Postoperative Boost Radiotherapy in Terms of Local Recurrence and Cosmetic Outcomes in Patients with Early-Stage Breast Cancer
    Gunay, Semra
    Kandemir, Ozge
    Yilmaz, Binnur Donmez
    Akan, Arzu
    Yalcin, Orhan
    INDIAN JOURNAL OF SURGERY, 2019, 81 (03) : 253 - 258
  • [48] Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis
    Matsuo, Yukinori
    Chen, Fengshi
    Hamaji, Masatsugu
    Kawaguchi, Atsushi
    Ueki, Nami
    Nagata, Yasushi
    Sonobe, Makoto
    Morita, Satoshi
    Date, Hiroshi
    Hiraoka, Masahiro
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) : 2932 - 2938
  • [49] Quality and Location of the Surgical Episode Mediate a Large Proportion of Socioeconomic-Based Survival Disparities in Patients with Resected Stage I-III Colon Cancer
    Swords, Douglas S.
    Bednarski, Brian K.
    Messick, Craig A.
    Tillman, Matthew M.
    Chang, George J.
    You, Y. Nancy
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (01) : 706 - 716
  • [50] Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016
    Bowles, Erin J. Aiello
    Ramin, Cody
    Buist, Diana S. M.
    Feigelson, Heather Spencer
    Weinmann, Sheila
    Veiga, Lene H. S.
    Bodelon, Clara
    Curtis, Rochelle E.
    Vo, Jacqueline B.
    de Gonzalez, Amy Berrington
    Gierach, Gretchen L.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (01) : 203 - 216